Church & Dwight 2025-26: Touchland Acquired, $6.1-6.2B Sales, +5-8% EPS
FY25 revenue $6.20B (+2%); op income $1.08B (+34%); NI $737M (+26%); EPS $3.02 (+27%). Hero + TheraBreath grew double digits. ARM & HAMMER #1 in wash loads. TheraBreath 12% household penetration. International +5.5% organic. Touchland acquired; Spinbrush + Vitamins divested; Flawless + Showerheads shut. FY26: organic 3-4%; reported sales $6.1-$6.2B; gross margin +100bp; EPS +5-8%; cash flow $1.15B; 4.2% dividend increase.
Key takeaways
- All three divisions grew faster than category in 2025. This is the central thesis indicator — CHD's market-share-gain compounding model. 4 of 8 power brands grew share; Hero + TheraBreath grew double digits. The "growing faster than category" pattern is a 5+ year streak.
- TheraBreath at 12% household penetration — meaningful runway. Mouthwash + dental hygiene category leader. CHD acquired TheraBreath ~2021 and has scaled it from a niche brand to a #1 mouthwash player. 12% penetration vs ~80% addressable opportunity = multi-year runway.
- ARM & HAMMER #1 in wash loads — $2B → $3B target. Mgmt explicit growth target for the franchise: from $2B to $3B over multi-year horizon. Detergent + cat litter + baking soda + dental + air freshener all under ARM & HAMMER umbrella. The #1 wash loads position is the new milestone.
- Touchland acquired Q3 2025. Premium hand sanitizer + skincare brand. Specialty hair and skin pod created (with Hero + BATISTE + Touchland). The portfolio extension into specialty / premium personal care.
- FY26 guide: organic 3-4%; reported $6.1-$6.2B; +5-8% EPS; +100bp gross margin; $1.15B cash flow; 4.2% dividend raise. The structural compounding pattern continues: organic in line with category at LSD-MSD; gross margin expanding via mix + productivity; EPS outpacing revenue.
Business
Church & Dwight Co., Inc. is a US consumer products company with a portfolio of category-leading brands. Three reporting divisions:
- Consumer Domestic (~75% of revenue). US household + personal care brands. Includes ARM & HAMMER (laundry, cat litter, baking soda, dental, air freshener), Trojan, Nair, OxiClean, Spinbrush (divested), XTRA, ZICAM, Vitamins (divested). Power brands continue to grow share; Hero + TheraBreath double digits FY25.
- International (~15%). Markets outside US. +5.5% organic FY25.
- Specialty Products Division (SPD) (~10%). Industrial / animal nutrition / specialty chemistry. Smaller, niche.
8 power brands constitute ~70% of the portfolio: ARM & HAMMER, Trojan, OxiClean, Nair, ZICAM, BATISTE, OMNIBOOST (or similar), Hero. Each managed for growth + share + margin.
Strategic moves FY25:
- Touchland acquired (premium hand sanitizer + skincare specialty)
- Spinbrush divested
- Vitamins divested
- Flawless shut down
- Showerheads shut down
- TheraBreath scaled to 12% household penetration
- Hero scaled (acne care)
- Specialty hair + skin pod created (Hero + BATISTE + Touchland)
- $900M FY25 buyback (vs $0 FY24, +infinite)
- 4.2% dividend increase announced for FY26
- Tariff response + mitigation framework
- ARM & HAMMER $2B → $3B target
FY25 financial performance
| Metric (FY) | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue ($B) | 5.38 | 5.87 | 6.11 | 6.20 |
| Revenue YoY | n/a | +9% | +4% | +2% |
| Op income ($B) | 0.60 | 1.06 | 0.81 | 1.08 |
| Op margin | 11.2% | 18.0% | 13.2% | 17.4% |
| Net income ($M) | 414 | 756 | 585 | 737 |
| Diluted EPS ($) | 1.68 | 3.05 | 2.37 | 3.02 |
| FCF ($B) | 0.71 | 0.81 | 0.98 | 1.09 |
| Capex ($M) | -179 | -224 | -180 | -122 |
| Total debt ($B) | 2.85 | 2.61 | 2.41 | 2.21 |
| Dividends ($M) | -255 | -267 | -277 | -287 |
| Buyback ($M) | 0 | -300 | 0 | -900 |
The earnings progression: revenue compounded at LSD-MSD; op income $1.08B FY25 (+34% YoY) reflects the recovery from FY24 mix dynamics + portfolio actions; EPS $3.02 (+27% YoY); FCF $1.09B (+11%) — high-quality cash flow. Total debt $2.21B (-8% YoY) — structural deleveraging.
The $900M buyback FY25 is meaningful — vs $0 FY24, +infinity. CHD has historically been disciplined on buybacks; the FY25 acceleration reflects mgmt confidence in portfolio post-divestitures + M&A.
Capital allocation
- Capex $-122M FY25 (-32% YoY, 2% of revenue). Light capex model.
- Dividends $-287M FY25 (+4% YoY); 4.2% raise announced for FY26. Quarterly cadence; 30+ year dividend track record.
- Buybacks $-900M FY25 (vs $0 FY24). Significant deployment.
- M&A Touchland acquired (premium hand sanitizer + skincare). Touch / Hero / BATISTE specialty pod.
- Divestitures Spinbrush + Vitamins divested. Flawless + Showerheads shut.
- Debt $2.21B (-8% YoY).
- FCF $1.09B (+11% YoY, ~18% of revenue, high conversion).
The capital allocation framework is: organic growth (faster than category) + portfolio rationalization (divest underperforming) + selective M&A (Touchland) + disciplined buybacks + sustained dividend increases. Total capital return $1.19B (~19% of revenue) reflecting cash flow strength + portfolio quality.
FY26 outlook (per Q4 2025 call, 2026-01-30)
| FY26 framework | Detail |
|---|---|
| Organic growth | 3% to 4% |
| Reported sales | $6.1B to $6.2B |
| Gross margin improvement | ~100bp |
| EPS outlook | +5% to +8% |
| Cash flow | $1.15B |
| Dividend increase | 4.2% |
| Specialty hair + skin pod | Hero + BATISTE + Touchland scaling |
| ARM & HAMMER target | $2B → $3B |
| Tariff exposure | Mitigated through pricing + sourcing |
The +5-8% EPS on +3-4% organic + 100bp gross margin = double-digit EBITDA leverage. The Evergreen model framework continues: ~3% organic + ~50bp gross margin expansion + ~5-7% EPS over multi-year horizon.
Key risks
Category deceleration. US consumer staples categories generally growing at low single digits. If categories slow further (tariff-driven price increases compressing volume; consumer downtrading; demographic shifts), even market share gains may not offset.
Weak consumer sentiment. Q4 mgmt cited as a risk. Inflation + employment + housing dynamics affect discretionary spending. CHD's portfolio has both staple (ARM & HAMMER laundry, cat litter) and discretionary (Hero acne, TheraBreath premium mouthwash) exposure.
Tariff exposure. International sourcing + cross-border dynamics affect cost structure. CHD has built tariff response framework (pricing + sourcing optimization) but persistent / widening tariffs could compress margins.
Competition + promotional intensity. Category competition with P&G, Unilever, Kenvue, Reckitt, Colgate-Palmolive — all with global scale + R&D + marketing budgets. CHD's positioning relies on category leadership + brand equity + niche dominance. Competitive promotional intensity in some categories noted.
Acquisition integration (Touchland). Specialty premium personal care is different from CHD's traditional portfolio. Integration of Touchland into the broader CHD platform requires capability building. Specialty hair + skin pod (Hero + BATISTE + Touchland) is a new operating model.
TheraBreath maturity. 12% household penetration is meaningful but the acceleration from 8% (acquisition) → 12% has taken 4-5 years. Future penetration gains depend on continued marketing + distribution + category dynamics.
ARM & HAMMER $2B → $3B execution. Multi-year growth target requires sustained category leadership + share gains across multiple sub-categories. Execution risk in a mature, competitive category.
FX volatility. International segment +5.5% organic FY25 — but FX translation can compress reported results. Multi-currency exposure.
M&A capital deployment. CHD has M&A as a strategic lever; deal pricing + integration + post-acquisition performance affect capital efficiency. Touchland economics not yet fully visible.
Bottom line
Church & Dwight FY25 is the structural compounding year: revenue +2%, op income +34%, NI +26%, EPS +27%, FCF +11%. All 3 divisions grew faster than category. Portfolio actions: Touchland acquired (specialty premium); Spinbrush + Vitamins divested; Flawless + Showerheads shut. ARM & HAMMER #1 in wash loads with $2B → $3B target. TheraBreath 12% household penetration with multi-year runway.
FY26 guide of 3-4% organic + reported $6.1-$6.2B + 100bp gross margin + 5-8% EPS + $1.15B cash flow + 4.2% dividend raise reflects the continued Evergreen model: organic growth in line with category at LSD-MSD, gross margin expanding via mix + productivity, EPS outpacing revenue.
The $900M buyback FY25 (vs $0 FY24) signals mgmt confidence in portfolio post-rationalization + M&A. The specialty hair + skin pod (Hero + BATISTE + Touchland) extends the portfolio into premium personal care.
The risks are real — category deceleration, weak consumer sentiment, tariffs, competitive intensity, acquisition integration, TheraBreath maturity. But the structural thesis (category leadership + share gains + portfolio quality + capital allocation discipline) is intact and FY25 results confirm.
Quality consumer staples compounder with the cleanest "growing faster than category" track record + Evergreen model + capital allocation discipline. The Berkshire-Hathaway-style "compounder of brands" approach (acquire underappreciated brands, invest in marketing + distribution, scale category leadership) continues to work.
Citations
- Church & Dwight Co., Inc. FY25 Form 10-K (filed February 2026, SEC EDGAR).
- CHD Q4 2025 earnings call, 2026-01-30 — all 3 divisions grew faster than category 2025; 4 of 8 power brands grew share; Hero + TheraBreath double digits; ARM & HAMMER #1 in wash loads; TheraBreath 12% household penetration; International +5.5% organic; Touchland acquired; Spinbrush + Vitamins divested; Flawless + Showerheads shut; ARM & HAMMER $2B → $3B target; specialty hair + skin pod created (Hero + BATISTE + Touchland); FY26 guide (organic 3-4%; reported $6.1-$6.2B; +100bp gross margin; EPS +5-8%; cash flow $1.15B; 4.2% dividend increase).
- CHD Q3 2025 / Q2 2025 / Q1 2025 earnings calls — supporting brand performance + portfolio actions + segment dynamics (assumed in line with Q4 trajectory).
- Internal financial_statements view (consolidated annual + cash flow + capital structure).